Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 25, 2025 04:00 ET | Source: Autolus Therapeutics plc

NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹

the National Institute for Health and Care Excellence (NICE) has published draft guidance recommending AUCATZYL®.
November 12, 2025 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Autolus announced its operational and financial results for the third quarter ended September 30, 2025
August 12, 2025 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Autolus announced its operational and financial results for the second quarter ended June 30, 2025.
May 08, 2025 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

Autolus announces its operational and financial results for the first quarter ended March 31, 2025.
April 25, 2025 12:06 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory
April 22, 2025 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Autolus will report Q1 2025 financial results on May 8, 2025.
March 20, 2025 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Autolus announces recent updates and financial results for the full year ended December 31, 2024.
January 17, 2025 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
January 13, 2025 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Provides Business Updates and 2025 Overview

Autolus announces business updates and an overview of 2025 milestones.
December 09, 2024 19:30 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024